HMGB1 and type 1 diabetes mellitus: In the current study, we want to determine the prophylactic and therapeutic efficacy of HMGB1-neutralising antibody at different stages of type 1 diabetes, including reversal of disease and protection of islet isografts from recurrent autoimmune attack, and dissect the underlying mechanisms.